NCT Number: NCT00287417
Early Ultrasound and Maternal Biochemical Markers to Evaluate the Risk of Down Syndrome During the First Trimester
The aim of the study is to evaluate the risk of Down syndrome during the first trimester of the pregnancy. The risk assessment is evaluated using early ultrasound and maternal biochemical markers.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
Female
Study type
Observational
Primary location
Département de Gynécologie-Obstétrique, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, Alsace, France
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Female > 18 years old
- Pregnant
Exclusion criteria
- Maternal age < 18 years old, twin pregnancy
Treatment and study plan
blood sample
OtherSponsors and collaborators
Lead sponsor
University Hospital, Strasbourg, France
Other
Registry information
Official study title
Nuchal Translucency Study - PAPP-A
Important dates
- Study start
- 2003
- Study completion
- 2011
- First posted
- Feb 6, 2006
- Registry last updated
- May 16, 2011
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
MOTOR PROFICIENCY AND HEALTH-RELATED FITNESS IN DOWN SYNDROME
NCT07702201
Abnormalities, Multiple, Chromosome Disorders
Giza, Eldoky, Egypt
View Trial DetailsTherapies for Down Syndrome Regression Disorder
NCT05662228
Abnormalities, Multiple, Autoimmune Diseases
Los Angeles, California, United States
View Trial DetailsThe (Cost)Effectiveness of a Social Robot for Persons With Problems in Daily Structure and Planning in Disability Care
NCT06592404
Abnormalities, Multiple, Autism Spectrum Disorder
Sittard, Limburg, Netherlands
View Trial DetailsLeucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease
NCT06206824
Abnormalities, Multiple, Alzheimer Disease
Gières, France
View Trial Details